GSK's Dova­to wins EU ap­proval; Red­Hill se­cures speedy re­view for H. py­lori drug

→ About two months af­ter win­ning speedy US ap­proval for its dual HIV reg­i­men — Dova­toGSK’s Vi­iV has se­cured the Eu­ro­pean nod. GSK …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.